Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Analysis
  5. Vantage Points

Vantage points

Evaluate

March 15, 2023

Europe rues SVB loss as a cornerstone life science supporter

With deeps links to the US likely severed, and HSBC’s risk appetite unknown, what does a future without Silicon Valley Bank look like?

Thumbnail
July 21, 2022

Private equity gets serious about drug development

Venture capital has the brains, private equity has the books – can they make lots of money?

Article image
Vantage logo
May 30, 2018

Reasons to be cautious about new haemophilia therapies

Roche's Hemlibra has impressed, but uptake might not be as fast as some hope.

Article image
Vantage logo
May 29, 2018

Canada’s medical cannabis ambition no laughing matter

Growing acceptance of medical marijuana could see cannabis companies coming after pharma sales.

Article image
Vantage logo
April 26, 2018

Preventive Alzheimer’s trials keep amyloid hope alive

Drugs have so far failed to make an impact in established Alzheimer's disease, so research is moving towards efforts to prevent the disorder.

Article image
Vantage logo
March 28, 2018

Vertex and orphan drugs test limits of US payers

Vertex's cystic fibrosis drugs are among the most expensive ever evaluated by the US Institute for Clinical and Economic Research.

Article image
Vantage logo
March 15, 2018

Solving the incremental innovation dilemma

Could pricing pressure lead to the end of incremental innovation – and why does this matter?

Article image
Vantage logo
March 06, 2018

As US hospitals consolidate their pharmacy muscles grow

Consolidation of hospital chains could give biopharma another powerful group of payers to contend with.

Article image
Vantage logo
January 23, 2018

Biotech gets creative about the pay cheque

Amid a backlash over the high prices of advanced therapies, biotech companies are coming up with new payment models.

Article image
Vantage logo
October 25, 2017

European approvals face delay from agency move

How the EMA's move out of London could impact European drug approvals.

Vantage logo
October 23, 2017

Vantage Point – Pricing battle shifts to states

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up